examined the role of 68Ga-PSMA-PET/CT-based elective radiotherapy, evaluating the data of 394 patients with oligo-recurrent 68Ga-PSMA-PET/CT-positive prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.